[Comparison of the Early Efficacy and Serious Adverse Events between CCCG-ALL 2015 and CCLG-ALL 2008 in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia].

Abstract

OBJECTIVE:

To evaluate the early efficacy and serious adverse events (SAE) related to chemotherapy of different protocols in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL), so as to improve the overall survival rate.

METHODS:

A comparison of the early efficacy and SAE was performed between pediatric patients treated with Chinese Children Cancer Group-ALL 2015 (CCCG-ALL 2015) protocol from January 2019 to June 2020 and those treated with Chinese Children Leukemia Group-ALL 2008 (CCLG-ALL 2008) protocol from January 2017 to December 2018.

RESULTS:

The remission rate before consolidation chemotherapy between the two groups was not significantly different (P=0.198), but the negative conversion rate of minimal residual disease (MRD) in CCLG-ALL 2008 group was significantly higher than that in CCCG-ALL 2015 group (P=0.000). The incidence of SAE in CCCG-ALL 2015 group was significantly lower than that in CCLG-ALL 2008 group (P=0.021), and the incidence of infection-related SAE was significantly higher in the latter (P=0.001), while the difference of non-infection-related SAE was not statistically significant (P=0.623). In addition, the treatment-related mortality in CCCG-ALL 2015 group was significantly lower than that in CCLG-ALL 2008 group (P=0.003).

CONCLUSION:

CCCG-ALL 2015 regimen reduces the intensity of chemotherapy, which can significantly decrease the chemotherapy-related SAE (especially infection-related SAE), as well as treatment-related mortality. However, the MRD negative conversion rate is low before consolidation treatment, and the overall long-term efficacy remains to be further observed.

• Authors: Li-Li Pan, Yong-Zhi Zheng, Shao-Hua LE, Xue-Ling Hua, Hao Zheng, Zai-Sheng Chen, Jian Li
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 30 Issue 3 (Jun 2022) ISSN: 1009-2137 [Print] China
• PMID: 35680796 (Publication Type: Journal Article)

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Disease-Free Survival
• Humans
• Neoplasm, Residual (drug therapy, etiology)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Prognosis
• Retrospective Studies
• Treatment Outcome